Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XJ-MK-002
- Development stage
- Phase 1
- Lead developer
- HemaCell Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
XJ-MK-002 is an investigational allogeneic cell therapy consisting of a suspension of megakaryocytes derived from human umbilical cord blood. The drug is developed using a proprietary platform for the ex vivo expansion and directed differentiation of megakaryocyte precursors. Upon intravenous infusion into the patient, these megakaryocytes undergo terminal differentiation and fragmentation into functional platelets within the circulatory system, a biological process driven by physiological regulation and hemodynamic shear stress. This mechanism is intended to rapidly elevate platelet levels in patients suffering from severe thrombocytopenia without the traditional reliance on donor platelet transfusions. XJ-MK-002 has received Orphan Drug Designation (ODD) from the US FDA for the treatment of Bernard-Soulier Syndrome (BSS) and is currently being evaluated in clinical trials for cancer therapy-induced thrombocytopenia.
- Other names
- Umbilical Cord Blood Megakaryocyte InjectionAllogeneic Megakaryocyte InjectionMegakaryocyte Injection
Beyond the preview
Go deeper on XJ-MK-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XJ-MK-002.